Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727839 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
A Phase 1 study, sponsored by Immorna Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05727839 is a Phase 1 study that has completed, run by Immorna Biotherapeutics. The registered enrollment target is 19 participants.
The verdict
NCT05727839, a Phase 1 study, has completed, sponsored by Immorna Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
Interventions
- DRUG JCXH-211 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-02-24 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05727839
The ClinicalTrials.gov registry entry for NCT05727839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immorna Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JCXH-211 Injection is the first listed.
NCT05727839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05727839 about?
NCT05727839 is a clinical study titled "Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors". : A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
What is the current status of trial NCT05727839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-02-24. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05727839?
The interventions under investigation include: JCXH-211 Injection (DRUG).
Who is sponsoring clinical trial NCT05727839?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.